Translate ideas into impact™
Explore current openings and get ready to prove that impossible isn’t.Unlimit with us™
Jan 10, 2023
De novo antibodies are here.
The ability to create new therapeutic antibodies in silico could potentially reduce the time it takes to get new drug candidates into the clinic by more than half, while also increasing their probability of success in the clinic. AI and synthetic biology are unlocking new opportunities to create such De novo antibodies — antibodies that bind to specific targets without using any training data of antibodies known to bind to those specific targets.
Absci has announced a breakthrough in generative AI drug creation: We are the first to design and validate De novo therapeutic antibodies with zero-shot generative AI.
Creating antibodies in silico with generative AI represents a major industry breakthrough on the path to fully De novo antibody design and our vision to deliver breakthrough therapeutics at the click of a button, for everyone.
In related work, Absci recently showed its ability to simultaneously optimize multiple parameters important to drug developability including binding affinity and naturalness score, a measure associated with drug developability and immunogenicity. More details on that work can be found here.
Please note that the preprint manuscript has not undergone peer review, the findings are provisional, and the conclusions may change.